Izalontamab brengitecan versus platinum chemotherapy in EGFR-mutated NSCLC
In a phase 3 trial in China, 432 participants with EGFR-mutated advanced non-squamous NSCLC received either izalontamab brengitecan or platinum-based chemotherapy. Median BICR-assessed progression-free survival was 11·1 months with izalontamab brengitecan versus 5·7 months with chemotherapy (HR 0·40, 95% CI 0·31-0·51).
Primary source
PubMed record of a Phase III journal article, October 26, 2026
Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.
Machine-summarized from the source above; not independently reported. How we use automation